Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

It is important that the medical profession play a significant role in critically evaluating the
use of diagnostic procedures and therapies as they are introduced and tested in the …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

The standing guideline writing committee along with the parent Task Force identified trials
and other key data through October 2011 that may impact guideline recommendations. On …

Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute
coronary syndromes, ticagrelor reduced the composite outcome of cardiovascular death …

Late-breaking clinical trials presented at the 2008 and 2009 annual scientific meetings of the
ACC, AHA, and European Society of Cardiology, as well as selected other data through April …

The cytochrome P450 (CYP) enzymes are major players in drug metabolism. More than
2,000 mutations have been described, and certain single nucleotide polymorphisms (SNPs) …

ciation (AHA) convened a writing committee. The ACCF and AHA adhere to a rigorous policy
regarding relationships with industry and other entities (RWI) of authors and peer reviewers …

Research on genes and medications has advanced our understanding of the genetic basis
of individual drug responses. The aim of pharmacogenomics is to develop strategies for …

Interindividual differences in drug disposition are important causes for adverse drug
reactions and lack of drug response. The majority of phase I and phase II drug-metabolizing …